Cytodyn Director Lishomwa C. Ndhlovu : Advisory/Sc
Post# of 154725
(Total Views: 670)
Posted On: 04/02/2024 8:28:00 PM
Cytodyn Director Lishomwa C. Ndhlovu : Advisory/Scientific Board Member: AbbVie Inc.; VIIV Healthcare
Very bottom of link:
https://vivo.weill.cornell.edu/display/cwid-lndhlovu
__________
Jan. 2022 publish:
" New and persistent cognitive symptoms are a common post-acute sequelae of SARS-CoV-2 infection (PASC) and can follow severe disease or mild illness."
Listed in Conflicts of Interest section:
"Dr. Ndhlovu received consulting fees from work as a scientific advisor for Abbvie, ViiV, and Cytodyn outside of the submitted work."
https://onlinelibrary.wiley.com/doi/10.1002/acn3.51498
___________
With hold lifted & NIH PASC funding, maybe Cytodyn gets a NIH grant & runs a LH trial via Abbvie.
Shall see....
Very bottom of link:
https://vivo.weill.cornell.edu/display/cwid-lndhlovu
__________
Jan. 2022 publish:
" New and persistent cognitive symptoms are a common post-acute sequelae of SARS-CoV-2 infection (PASC) and can follow severe disease or mild illness."
Listed in Conflicts of Interest section:
"Dr. Ndhlovu received consulting fees from work as a scientific advisor for Abbvie, ViiV, and Cytodyn outside of the submitted work."
https://onlinelibrary.wiley.com/doi/10.1002/acn3.51498
___________
With hold lifted & NIH PASC funding, maybe Cytodyn gets a NIH grant & runs a LH trial via Abbvie.
Shall see....
(8)
(0)